The Biosimilar product is used for treatment for an aemia due to cancer chemaptherapy and kidney disorders
BANGALORE, India I November 19, 2013 I Avesthagen Pharma AG (APAG) announces an agreement with Elpen Pharmaceutical Co. Inc., a leader in life-sciences, for the distribution of AVDESP, a biosimilar product in seven EU and six non-EU territories namely Greece, Cyprus, Bulgaria, Romania, Croatia, Slovenia, Slovakia, Serbia, Bosnia, FRYOM, Albania, Montenegro and Kosovo with a collective population base of over 70 million.
AVDESP, a Biosimilar for Darbepoetin alfa Aranesp® will be used for the treatment of anaemia resulting from chronic kidney disorders and cancer chemotherapy. “We are excited about this alliance as we start our marketing in so me most interesting countries, it will give us an opportunity to know these markets and interact with its people”, said Dr Villoo Morawala Patell, Chairperson, APAG.
The current global sales for the product are in excess of US$2.5 Billion and APAG hopes to price AVDESP for it to come within the reach of a wider global community. “The company is committed to deliver affordable healthcare for humanity”, adds Dr Patell. APAG is currently engaged with many other opportunities for a number of its ‘Biosimilars’ and ‘Biobetters’ with strong principals in several countries. APAG is working with different outsourcing organizations to make sure the product come to the market at the earliest. APAG has identified Syngene International Ltd. for fill and finish, and Kemwell Bioharma as a CMO (Contract Manufacturing Organization). And PRA International, a global CRO to conduct the carry out the Phase I Clinical Trial in The Netherlands followed by Phase III in I ndia. This deal is of primary importance as APAG establishes its presence as a developer and marketer of its significant Biosimilar pipeline.
Avesthagen Pharma AG (APAG) and its 100% owned subsidiary Avesthagen Pharma India Pvt Ltd (APIPL) is a key player in the Targeted Therapeutic space. Its journey has started as a spin-out from Avesthagen Limited carrying a formidable portfolio of 8 biosimilars.
Both companies stressed that they are excited with the new deal, which marks the beginning of a long and fruitful cooperation.
SOURCE: Avesthagen
Post Views: 220
The Biosimilar product is used for treatment for an aemia due to cancer chemaptherapy and kidney disorders
BANGALORE, India I November 19, 2013 I Avesthagen Pharma AG (APAG) announces an agreement with Elpen Pharmaceutical Co. Inc., a leader in life-sciences, for the distribution of AVDESP, a biosimilar product in seven EU and six non-EU territories namely Greece, Cyprus, Bulgaria, Romania, Croatia, Slovenia, Slovakia, Serbia, Bosnia, FRYOM, Albania, Montenegro and Kosovo with a collective population base of over 70 million.
AVDESP, a Biosimilar for Darbepoetin alfa Aranesp® will be used for the treatment of anaemia resulting from chronic kidney disorders and cancer chemotherapy. “We are excited about this alliance as we start our marketing in so me most interesting countries, it will give us an opportunity to know these markets and interact with its people”, said Dr Villoo Morawala Patell, Chairperson, APAG.
The current global sales for the product are in excess of US$2.5 Billion and APAG hopes to price AVDESP for it to come within the reach of a wider global community. “The company is committed to deliver affordable healthcare for humanity”, adds Dr Patell. APAG is currently engaged with many other opportunities for a number of its ‘Biosimilars’ and ‘Biobetters’ with strong principals in several countries. APAG is working with different outsourcing organizations to make sure the product come to the market at the earliest. APAG has identified Syngene International Ltd. for fill and finish, and Kemwell Bioharma as a CMO (Contract Manufacturing Organization). And PRA International, a global CRO to conduct the carry out the Phase I Clinical Trial in The Netherlands followed by Phase III in I ndia. This deal is of primary importance as APAG establishes its presence as a developer and marketer of its significant Biosimilar pipeline.
Avesthagen Pharma AG (APAG) and its 100% owned subsidiary Avesthagen Pharma India Pvt Ltd (APIPL) is a key player in the Targeted Therapeutic space. Its journey has started as a spin-out from Avesthagen Limited carrying a formidable portfolio of 8 biosimilars.
Both companies stressed that they are excited with the new deal, which marks the beginning of a long and fruitful cooperation.
SOURCE: Avesthagen
Post Views: 220
